These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25068074)

  • 21. High-Throughput Liquid Chromatography-Tandem Mass Spectrometry Quantification of Glycosaminoglycans as Biomarkers of Mucopolysaccharidosis II.
    Wang J; Bhalla A; Ullman JC; Fang M; Ravi R; Arguello A; Thomsen E; Tsogtbaatar B; Guo JL; Skuja LL; Dugas JC; Davis SS; Poda SB; Gunasekaran K; Costanzo S; Sweeney ZK; Henry AG; Harris JM; Henne KR; Astarita G
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III.
    de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N
    Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous quantification of selected glycosaminoglycans by butanolysis-based derivatization and LC-SRM/MS analysis for assessing glycocalyx disruption in vitro and in vivo.
    Matyjaszczyk-Gwarda K; Kij A; Olkowicz M; Fels B; Kusche-Vihrog K; Walczak M; Chlopicki S
    Talanta; 2022 Feb; 238(Pt 1):123008. PubMed ID: 34857342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of dermatan sulfate and heparan sulfate concentrations in serum, cerebrospinal fluid and urine in patients with mucopolysaccharidosis type I receiving intravenous and intrathecal enzyme replacement therapy.
    Zhang H; Dickson PI; Stiles AR; Chen AH; Le SQ; McCaw P; Beasley J; Millington DS; Young SP
    Clin Chim Acta; 2020 Sep; 508():179-184. PubMed ID: 32442432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An improved method for glycosaminoglycan analysis by LC-MS/MS of urine samples collected on filter paper.
    Auray-Blais C; Lavoie P; Zhang H; Gagnon R; Clarke JT; Maranda B; Young SP; An Y; Millington DS
    Clin Chim Acta; 2012 Apr; 413(7-8):771-8. PubMed ID: 22285314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An At-Risk Population Screening Program for Mucopolysaccharidoses by Measuring Urinary Glycosaminoglycans in Taiwan.
    Lin HY; Lee CL; Lo YT; Tu RY; Chang YH; Chang CY; Chiu PC; Chang TM; Tsai WH; Niu DM; Chuang CK; Lin SP
    Diagnostics (Basel); 2019 Oct; 9(4):. PubMed ID: 31590383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disaccharide analysis of glycosaminoglycans using hydrophilic interaction chromatography and mass spectrometry.
    Gill VL; Aich U; Rao S; Pohl C; Zaia J
    Anal Chem; 2013 Jan; 85(2):1138-45. PubMed ID: 23234263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Multiplex Assay for the Diagnosis of Mucopolysaccharidoses and Mucolipidoses.
    Langereis EJ; Wagemans T; Kulik W; Lefeber DJ; van Lenthe H; Oussoren E; van der Ploeg AT; Ruijter GJ; Wevers RA; Wijburg FA; van Vlies N
    PLoS One; 2015; 10(9):e0138622. PubMed ID: 26406883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of Glycosaminoglycans Using Mass Spectrometry.
    Staples GO; Zaia J
    Curr Proteomics; 2011; 8(4):325-336. PubMed ID: 25705143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry.
    Zhang H; Young SP; Auray-Blais C; Orchard PJ; Tolar J; Millington DS
    Clin Chem; 2011 Jul; 57(7):1005-12. PubMed ID: 21576268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Quantification of Glycosaminoglycans: A Comparison of HPLC, Carbazole, and Alcian Blue Methods.
    Frazier SB; Roodhouse KA; Hourcade DE; Zhang L
    Open Glycosci; 2008 Jan; 1():31-39. PubMed ID: 20640171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LC-MS/MS method for simultaneous quantification of heparan sulfate and dermatan sulfate in urine by butanolysis derivatization.
    Forni G; Malvagia S; Funghini S; Scolamiero E; Mura M; Della Bona M; Villanelli F; Damiano R; la Marca G
    Clin Chim Acta; 2019 Jan; 488():98-103. PubMed ID: 30395869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Newborn screening for mucopolysaccharidoses: Measurement of glycosaminoglycans by LC-MS/MS.
    Stapleton M; Kubaski F; Mason RW; Shintaku H; Kobayashi H; Yamaguchi S; Taketani T; Suzuki Y; Orii K; Orii T; Fukao T; Tomatsu S
    Mol Genet Metab Rep; 2020 Mar; 22():100563. PubMed ID: 31956510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neonatal Mass Urine Screening Approach for Early Detection of Mucopolysaccharidoses by UPLC-MS/MS.
    Menkovic I; Marchand AS; Boutin M; Auray-Blais C
    Diagnostics (Basel); 2019 Nov; 9(4):. PubMed ID: 31752121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses.
    Lin HY; Lee CL; Lo YT; Wang TJ; Huang SF; Chen TL; Wang YS; Niu DM; Chuang CK; Lin SP
    Mol Genet Genomic Med; 2018 Nov; 6(6):982-992. PubMed ID: 30296009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans.
    de Ru MH; van der Tol L; van Vlies N; Bigger BW; Hollak CE; Ijlst L; Kulik W; van Lenthe H; Saif MA; Wagemans T; van der Wal WM; Wanders RJ; Wijburg FA
    J Inherit Metab Dis; 2013 Mar; 36(2):247-55. PubMed ID: 22991166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combined use of enzyme activity and metabolite assays as a strategy for newborn screening of mucopolysaccharidosis type I.
    Polo G; Gueraldi D; Giuliani A; Rubert L; Cazzorla C; Salviati L; Marzollo A; Biffi A; Burlina AP; Burlina AB
    Clin Chem Lab Med; 2020 Nov; 58(12):2063-2072. PubMed ID: 32432561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI.
    Auray-Blais C; Bhérer P; Gagnon R; Young SP; Zhang HH; An Y; Clarke JT; Millington DS
    Mol Genet Metab; 2011 Jan; 102(1):49-56. PubMed ID: 20934363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis of Mucopolysaccharidoses and Mucolipidosis by Assaying Multiplex Enzymes and Glycosaminoglycans.
    Arunkumar N; Vu DC; Khan S; Kobayashi H; Ngoc Can TB; Oguni T; Watanabe J; Tanaka M; Yamaguchi S; Taketani T; Ago Y; Ohnishi H; Saikia S; Álvarez JV; Tomatsu S
    Diagnostics (Basel); 2021 Jul; 11(8):. PubMed ID: 34441282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acidolysis-based component mapping of glycosaminoglycans by reversed-phase high-performance liquid chromatography with off-line electrospray ionization-tandem mass spectrometry: evidence and tags to distinguish different glycosaminoglycans.
    Zhu H; Chen X; Zhang X; Liu L; Cong D; Zhao X; Yu G
    Anal Biochem; 2014 Nov; 465():63-9. PubMed ID: 25086363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.